利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.021 秒)

    Process for the preparation of solid polymeric stabilizer compounds
    3.
    发明授权
    Process for the preparation of solid polymeric stabilizer compounds 失效
    固体高分子稳定剂化合物的制备方法

    公开(公告)号：US4833211A

    公开(公告)日：1989-05-23

    申请号：US19881

    申请日：1987-02-27

    申请人： Arnaldo Roggero ,  Mario Clerici ,  Guglielmo Bertolini

    发明人： Arnaldo Roggero ,  Mario Clerici ,  Guglielmo Bertolini

    IPC分类号： C08L101/00 ,  C08F8/10 ,  C08F212/08 ,  C09K3/00

    CPC分类号： C08F8/10

    摘要： Solid polymeric stabilizer compound containing the hydroxybenzophenone function, having the general formula (I): ##STR1## wherein: m=from 0.01 to 0.99 (preferably from 0.1 to 0.6);l=from 0.99 to 0.01 (preferably from 0.9 to 0.4):m+l=1;R=H, --OH, --OR" (R"+(C.sub.1 -C.sub.20)-alkyl; aryl, alkylaryl cycloalkyl). halogen, (C.sub.1 -C.sub.20)-alkyl, cycloalkyl;R'=H, (C.sub.1 -C.sub.20)-alkyl, cycloalkyl.Also the process for preparing said solid polymeric stabilizers and the stabilized polymeric compositions comprising at least an organic polymer and a stabilizing amount of said solid polymeric stabilizers are disclosed.

    摘要翻译： 具有通式（I）的羟基二苯甲酮功能的固体高分子稳定剂化合物：其中：m = 0.01〜0.99（优选为0.1〜0.6）。 l = 0.99至0.01（优选0.9至0.4）：m + 1 = 1; R = H，-OH，-OR“（R”+（C 1 -C 20） - 烷基;芳基，烷基芳基环烷基）。 卤素，（C 1 -C 20） - 烷基，环烷基; R'= H，（C 1 -C 20） - 烷基，环烷基。 还公开了制备所述固体聚合物稳定剂和包含至少一种有机聚合物和稳定量的所述固体聚合物稳定剂的稳定化聚合物组合物的方法。

    TREATMENT WITH CYTOKINES
    6.
    发明申请
    TREATMENT WITH CYTOKINES 审中-公开
    用细胞因子治疗

    公开(公告)号：US20120214866A1

    公开(公告)日：2012-08-23

    申请号：US13356374

    申请日：2012-01-23

    申请人： Mario Clerici ,  Giorgio Annoni

    发明人： Mario Clerici ,  Giorgio Annoni

    IPC分类号： C12Q1/68 ,  C07H21/04 ,  C07K14/52 ,  C07K14/54 ,  A61P25/28 ,  C07K14/55 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  A61K48/00 ,  C07K14/545

    CPC分类号： C12Q1/6883 ,  A61K38/19 ,  C12Q2600/156 ,  C12Q2600/172

    摘要： An inflammatory process is suggested to be involved in the pathogenesis of Alzheimer's disease (AD), a neurodegenerative disorder characterized by the presence of neuritic plaques within the cerebral cortex that are mainly composed of a small insoluble protein of 40-42 aminoacids (amyloid protein). Amyloid-specific Interleukin-10 (IL-10) generation is found to be selectively and significantly reduced in AD patients (p=0.023). The genotype associated with high IL-10 production is extremely infrequent in AD individuals (2% vs. 28%). The presence of low/intermediate-IL-10-producing genotypes (GCC/ATA; ATA/ATA) was associated with an earlier age at disease onset and (ACC/ACC; ACC/ATA) with an accelerated rate of disease progression/severity and with amyloid-specific impairment of IL-10 production. This relationship is independent of ApoE gene polymorphism. These results support the use of anti-inflammatory compounds in the therapy of this disease.

    摘要翻译： 建议炎症过程参与阿尔茨海默病（AD）的发病机制，阿尔茨海默氏病（AD）是一种以大脑皮层内存在神经突斑为特征的神经变性疾病，主要由40-42个氨基酸（淀粉样蛋白）的小不溶性蛋白质组成， 。 发现AD患者淀粉样蛋白特异性白细胞介素-10（IL-10）代被选择性地显着降低（p = 0.023）。 与高IL-10产生相关的基因型在AD个体中极少（2％vs. 28％）。 低/中等IL-10产生基因型（GCC / ATA; ATA / ATA）的存在与疾病发病的早期年龄和（ACC / ACC; ACC / ATA）相关，具有加速的疾病进展/严重程度 并具有IL-10产生的淀粉样蛋白特异性损伤。 这种关系与ApoE基因多态性无关。 这些结果支持在治疗这种疾病中使用抗炎化合物。

    .sigma. AND .pi. ORGANIC COMPLEXES OF TRANSITION METALS AND PROCESS FOR THE PREPARATION THEREOF
    8.
    发明授权
    .sigma. AND .pi. ORGANIC COMPLEXES OF TRANSITION METALS AND PROCESS FOR THE PREPARATION THEREOF 失效
    {94 {0和{90 {0有机金属过渡复合物及其制备方法

    公开(公告)号：US4042609A

    公开(公告)日：1977-08-16

    申请号：US654350

    申请日：1976-02-02

    申请人： Emilio Perrotti ,  Mario Clerici

    发明人： Emilio Perrotti ,  Mario Clerici

    IPC分类号： B01J31/22 ,  B01J31/24 ,  C07C5/03 ,  C07F9/00 ,  C07F15/00 ,  C07F13/00

    CPC分类号： B01J31/2291 ,  B01J31/2295 ,  B01J31/24 ,  B01J31/2404 ,  C07C5/03 ,  C07F15/0033 ,  C07F9/00 ,  B01J2231/641 ,  B01J2231/70 ,  B01J2531/74 ,  B01J2531/827 ,  C07C2531/22

    摘要： A compound having catalytic properties which is a .sigma. or .pi. organic complex of a transition metal represented by the general formula: M (A).sub.n (L-C) (L).sub.m, wherein M is Ir or Re; L is a member of the group consisting of alkyl and aryl phosphines; (L-C) is (a) an alkyl or aryl phosphine ligand wherein a C-H bond is reacted with the central M atom to which the ligand is coordinated, and a metal-carbon bond is formed, or (b) a .pi.-allyl radical; A is a linear monoolefin having from 2 to 5 carbon atoms or a cyclic monoolefin having from 6 to 8 carbon atoms; n is a number in the range of 0 to 2 and is always zero when L-C is a .pi.-allyl radical; and m is a number from 1 to 3 which satisfies the valence of M, is prepared by reacting a hydride complex represented by the general formula: MHLn.sub.1 wherein M and L have the meaning given above, x is in the range from 5 to 7 and n.sub.1 is a number from 2 to 3 which satisfies the valence of M, with a linear monoolefin having from 2 to 5 carbon atoms or a cyclic monoolefin having from 6 to 8 carbon atoms.

    摘要翻译： 具有催化性质的化合物，其为由通式M（A）n（L-C）（L）m表示的过渡金属的σ或π有机络合物，其中M为Ir或Re; L是由烷基和芳基膦组成的组的成员; （L-C）是（a）烷基或芳基膦配体，其中C-H键与配位体配位的中心M原子反应，形成金属 - 碳键，或（b）吡咯烷基; A是具有2至5个碳原子的直链单烯烃或具有6至8个碳原子的环状单烯烃; n为0〜2的数，当L-C为吡啶基时，该数为0。 m为1〜3的数，其满足M的化合价，通过使由通式MHLn1表示的氢化物配合物反应制备，其中M和L具有上述含义，x在5至7的范围内， n1是2至3的数，其满足M的价数，具有2至5个碳原子的直链单烯烃或具有6至8个碳原子的环状单烯烃。

    Treatment with cytokines
    10.
    发明申请
    Treatment with cytokines 审中-公开
    用细胞因子治疗

    公开(公告)号：US20050260767A1

    公开(公告)日：2005-11-24

    申请号：US10516421

    申请日：2003-05-30

    申请人： Mario Clerici ,  Giorgio Annoni

    发明人： Mario Clerici ,  Giorgio Annoni

    IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K38/19 ,  A61K38/20 ,  A61K45/00 ,  A61K48/00 ,  A61P3/10 ,  A61P11/06 ,  A61P19/02 ,  A61P21/04 ,  A61P25/00 ,  A61P25/02 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/18 ,  A61P37/02 ,  A61P43/00 ,  C12N15/24 ,  C12Q1/68 ,  C12Q1/6883 ,  G01N33/543

    CPC分类号： C12Q1/6883 ,  A61K38/19 ,  C12Q2600/156 ,  C12Q2600/172

    摘要： An inflammatory process is suggested to be involved in the pathogenesis of Alzheimer's disease (AD), a neurodegenerative disorder characterized by the presence of neuritic plaques within the cerebral cortex that are mainly composed of a small insoluble protein of 40-42 amino acids (amyloid protein). The biological correlates of this process are nevertheless not clear. Interleukin-10 (IL-10) is a cytokine that suppresses T lymphocytes and cell-mediated immunity in humans and mice and has potent anti-inflammatory properties. To verify if IL-10 production would be impaired in AD patients we stimulated PBMC of 47 patients and 25 age-matched healthy controls (HC) with a mitogen, a recall antigen or with amyloid peptides. IL-2 production was measured as well in the same cultural conditions. Results showed that amyloid-specific IL-10 generation is selectively and significantly reduced in AD patients (p=0.023). Analyses on the alleles of the IL-10 gene revealed that the genotype associated with high IL-10 production is extremely infrequent in AD individuals (2% vs. 28%). The presence of low/intermediate IL-10-producing genotypes (GCC/ATA; ATA/ATA) was associated with an earlier age at disease onset and (ACC/ACC; ACC/ATA) with an accelerated rate of disease progression. These data shed light on the biology of the inflammatory process involved in the pathogenesis of AD by showing that the presence of low-IL-10-allelic isoforms results in an amyloid-specific impairment of IL-10 production and is associated with the clinical severity of AD. These results lend support to the use of anti-inflammatory compounds in the therapy of this disease.

    摘要翻译： 建议炎症过程参与阿尔茨海默病（AD）的发病机制，阿尔茨海默病（AD）是一种以大脑皮层内存在神经突斑为特征的神经变性疾病，主要由40-42个氨基酸的小不溶性蛋白质（淀粉样蛋白 ）。 然而，这一过程的生物相关性尚不清楚。 白细胞介素-10（IL-10）是抑制人类和小鼠中T淋巴细胞和细胞介导的免疫的细胞因子，具有强大的抗炎特性。 为了验证AD患者IL-10的产生是否受损，我们用有丝分裂原，召回抗原或淀粉样蛋白肽刺激47例患者和25例年龄匹配的健康对照（HC）的PBMC。 在相同的文化条件下也测量了IL-2的产生。 结果显示，AD患者淀粉样蛋白特异性IL-10的产生有明显的降低（p = 0.023）。 对IL-10基因等位基因的分析显示，AD患者与高IL-10产生相关的基因型极少（2％vs. 28％）。 低/中间IL-10产生基因型（GCC / ATA; ATA / ATA）的存在与疾病发病年龄和ACC（ACC / ACC）/ ACC（ACC / ATA）的发病率相关。 通过显示低IL-10等位基因异构体的存在导致IL-10产生的淀粉样蛋白特异性损伤，并且与临床严重程度相关联，这些数据揭示了涉及AD发病机制的炎症过程的生物学特征 的AD。 这些结果支持在治疗这种疾病中使用抗炎化合物。